As we close another year of unprecedented challenges and achievements, I’m honored to share with you Treatment Action Group’s (TAG) 2022 Annual Report. This showcases the remarkable work of our staff, board, partners, and supporters in advancing research and policy for HIV, tuberculosis (TB), and viral hepatitis (HCV).
Despite the ongoing COVID-19 pandemic that has disrupted health systems and exacerbated health inequities around the world, TAG remained steadfast in its mission to end these three epidemics with science-based advocacy and community engagement. In 2022, some of our highlights included:
- Launching a new, five-year research project funded by USAID to improve access to TB diagnostics, treatment, and research;
- Advocating for and achieving equitable pricing and distribution of GeneXpert tests for TB and COVID-19;
- Hosting webinars on new developments in HIV cure research, TB vaccine development, and long-acting technologies;
- Publishing updated information on HIV cure research trials;
- Supporting community advisory boards and civil society organizations to engage in research, prevention, and treatment advocacy;
- Accelerating rollout of vaccines and treatments for mpox (formerly monkeypox);
- Returning in-person to celebrate TAG’s 30th anniversary at the Research in Action Awards, which honored the achievements of Laura Morrison, Dr. Kelly Elise Dooley, Dr. Amita Gupta, and Ann Northrop.
These are just a few examples of TAG’s impact in 2022. You can read more about our work in this report, which features updates from our programs that further highlight the importance of TAG’s continued efforts.
On behalf of TAG’s board, staff, and partners, I thank you for your commitment to our mission. None of this would have been possible without your generous support. Thank you for being part of our community. As we look ahead, I invite you to join us and help ensure that no one is left behind in the quest for health justice. Together we can continue to make a difference.
TAG Board President